ArticleScientific reports2022
Associations of cognitive dysfunction with motor and non-motor symptoms in patients with de novo Parkinson's disease.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- Altered cerebrovascular haemodynamics in Parkinson's disease: Insights from 4D flow MRI.NPJ Parkinson's disease · 2026Article
- Parkinson's research with inclusion, diversity and equity (PRIDE): examining Parkinson's disease symptoms among LGBTQ+ and non-LGBTQ+ adults.Frontiers in public health · 2026Article
- Organosulfur Compounds: Potential Therapeutics for Parkinson's Disease.CNS & neurological disorders drug targets · 2026Review
- Factors associated with self- perceived speech impairment inFrontiers in aging neuroscience · 2026Article
- Hippocampal functional imaging-derived radiomics features for diagnosing cognitively impaired patients with Parkinson's disease.BMC neuroscience · 2025Article
- Early Detection and Management of Cognitive Impairment in Parkinson's Disease: A Predictive Model Approach.Brain and behavior · 2025Article
- Article
- Brain fog in Parkinson's disease: unraveling mechanisms and measuring impact.Frontiers in neurology · 2025Article
- Advances in autonomic dysfunction research in Parkinson's disease.Frontiers in aging neuroscience · 2025Review
- Fatigue and neuropsychiatric symptoms in Parkinson's disease: a narrative review.Frontiers in neurology · 2025Review
- Prevalence, associated factors and impact of mild cognitive impairment in hospitalized older adults with Parkinson's disease: a cross-sectional study.Frontiers in aging neuroscience · 2025Article
- Sex differences in depression in Parkinson's disease: cognitive dysfunction and female-specific associations.Frontiers in neuroscience · 2025Article
- Balance and gait disorders in de novo Parkinson's disease: support for early rehabilitation.Journal of neurology · 2024Article
- New insights on the link between Epstein‑Barr virus infection and cognitive decline in neurodegenerative diseases (Review).Experimental and therapeutic medicine · 2024Review
- Association between autonomic dysfunction with motor and non-motor symptoms in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Article
- Sleep disorders cause Parkinson's disease or the reverse is true: Good GABA good night.CNS neuroscience & therapeutics · 2024Review
- Associations between cognitive screening performance and motor symptoms in Parkinson's disease:a systematic review and meta-analysis.Dementia & neuropsychologia · 2024Review
- Improving Functional Capacity and Quality of Life in Parkinson's Disease Patients through REAC Neuromodulation Treatments for Mood and Behavioral Disorders.Journal of personalized medicine · 2023Article
- Both Motor and Non-Motor Fluctuations Matter in the Clinical Management of Patients with Parkinson's Disease: An Exploratory Study.Journal of personalized medicine · 2023Article
- Aβ1-42-containing platelet-derived extracellular vesicle is associated with cognitive decline in Parkinson's disease.Frontiers in aging neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk factors of mild cognitive impairment (MCI) in patients with de novo Parkinson's disease (PD) remain unclear. Therefore, the objective of this study was to compare motor and non-motor symptoms between de novo patients with PD with and without MCI. Moreover, detailed relationships between each cognitive deficit and other clinical characteristics in de novo patients with PD were investigated. Consecutive patients with de novo PD were retrospectively enrolled in this study. Motor symptoms were assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) part-III and the Hoehn and Yahr (HY) stage. Non-motor symptoms including depression, anxiety, fatigue, and autonomic dysfunction were measured using representative questionnaires. Motor symptoms, depression, and dysautonomia were associated with MCI in de novo patients with PD. Compared with the non-MCI group with PD, the MCI group with PD had higher scores of UPDRS-III, HY stage, depression, and dysautonomia, but not fatigue or anxiety. Both UPDRS-III and HY stage were significantly linked to all cognitive deficits except attention. Logistic regression analysis showed that depression was associated with memory, visuospatial, and executive impairment, and dysautonomia was related to visuospatial and executive impairment. The results of this study suggest that cognitive impairment in PD might have a different relationship pattern to the motor and some non-motor symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.